Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897075 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
A Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT03897075 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 99 participants.
The verdict
NCT03897075, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
Interventions
- DRUG Placebo
- DRUG Tildrakizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897075
The ClinicalTrials.gov registry entry for NCT03897075 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03897075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03897075 about?
NCT03897075 is a clinical study titled "Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis". Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
What is the current status of trial NCT03897075?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2021-05-13. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT03897075?
The interventions under investigation include: Placebo (DRUG), Tildrakizumab (DRUG).
Who is sponsoring clinical trial NCT03897075?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.